Enhanced brain levels of 8,12-iso-iPF2α-VI differentiate AD from frontotemporal dementia

Neurology

Volumn 61, Issue 4, 2003, Pages 475-478

  Yao, Y ^a   Zhukareva, V ^a   Sung, S ^a   Clark, C M ^a   Rokach, J ^b   Lee, V M Y ^a   Trojanowski, J Q ^a   Praticò, Domenico ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Florida Institute of Technology   (United States)

^c Center for Experimental Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8,12 ISOPROSTAGLANDIN F2 ALPHA VI; ISOPROSTANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIPID BRAIN LEVEL; LIPID PEROXIDATION; MALE; MASS SPECTROMETRY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; TEMPORAL CORTEX;

EID: 0042932786     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000070185.02546.5D     Document Type: Article

References (28)

1. Praticò D. Alzheimer's disease and oxygen radicals: new insights. Biochem Pharmacol 2002;63:563-567.
2. McKhann GM, Grossman M, Albert MS, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of work group on frontotemporal dementia and Pick's disease. Ann Neurol 2001;58:1803-1809.
3. Knopman DS. Overview of dementia lacking distinctive histology: pathological designation of a progressive dementia. Dementia 1993;4:132-136.
4. Giannakopoulos P, Holf PR, Bouras C. Dementia lacking distinctive histopathology: clinicopathological evaluation of 32 cases. Acta Neuropathol 1995;89:346-355.
5. Mann DMA, South PW, Snowden JS, Neary D. Dementia of frontal lobe type-neuropathology and immunohistochemistry. J Neurol Neurosurg Psychiatry 1993;56:605-614.
6. Arnold SE. Cellular and molecular pathology of the frontal dementias. In: Clark CM, Trojanowski JQ, eds. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill, 2000;291-301.
7. Castellani RJ, Smith MA, Richey PL, et al. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res 1995;696:268-271.
8. Gerst JL, Siedlak SL, Numonura A, et al. Role of oxidative stress in frontotemporal dementia. Dement Geriatr Cogn Disord 1999;10:85-87.
9. Praticò D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. Tr Endocrinol Metab 2001;12:243-247.
10. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation. FASEB J 1998;12:1777-1783.
11. Montine TJ, Markesbery WR, Zackert W, et al. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or apoE genotype in Alzheimer's disease patients. Am J Pathol 1999;155:863-868.
12. 2α-VI in Alzheimer's disease: correlation of a non-invasive index of lipid peroxidation with disease severity. Ann Neurol 2000;48:809-812.
13. Lowe J, Mayer RJ, Landon M. Ubiquitin in neurodegenerative disease. Brain Pathol 1993;3:55-65.
14. Praticò D, Delanty N. Oxidative injury of the central nervous system: focus on Alzheimer's disease. Am J Med 2000;109:577-585.
15. Norton WT, Aquino DA, Hozumi I, et al. Quantitative aspects of reactive gliosis: a review. Neurochem Res 1992;17:877-885.
16. Arnold SE, Han LY, Clark CM, et al. Quantitative neurohistological features of frontotemporal degeneration. Neurobiol Aging 2001;21:913-919.
17. Praticò D. The in vivo measurement of the redox state. Lipids 2001;36:45-47.
18. 2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation. Atherosclerosis 1999;147:1-10.
19. Palmer AM, Burns MA. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res 1994;645:338-342.
20. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995;45:1594-1601.
21. Albers DS, Augood SJ, Martin DM, et al. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. J Neurochem 1999;73:881-884.
22. Albers DS, Augood SJ, Park LCH, et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem 2000;74:878-881.
23. Odetti P, Garibaldi S, Norese R, et al. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol 2000;59:393-397.
24. Montine KS, Kim PJ, Olson SJ, et al. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 1997;56:866-871.
25. Praticò D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment. A possible predictor of Alzheimer Disease. Arch Neurol 2002;59:972-976.
26. Smith MA, Harris PLR, Sayre LM, et al. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-2657.
27. Yan SD, Chen X, Schmidt AM, et al. Glycated tau protein in Alzheimer's disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787-7791.
28. Nunomura A, Perry G, Pappolla MA, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999;19:1959-1964.